BC Week In Review | Oct 22, 2012
Clinical News

R4929: Development discontinued

In its 3Q12 earnings, Roche said that it discontinued development of RG4929, which was in Phase II testing for metabolic diseases. Roche (SIX:ROG; OTCQX:RHHBY), Basel, Switzerland   Product: R4929, RG4929   Business: Endocrine/Metabolic   Molecular...
BC Innovations | Nov 10, 2011
Targets & Mechanisms

Saving the brain

In 2010, the American Academy of Pediatrics advised against postnatal use of high-dose dexamethasone, a powerful glucocorticoid used to boost circulation and lung function in preterm infants, because of the risk of stunted brain development....
BC Innovations | Apr 2, 2009
Distillery Therapeutics

Indication: Cancer

This week in therapeutics Indication Target/marker/pathway Summary Licensing status Publication and contact information Cancer Colorectal cancer 11b-Hydroxysteroid dehydrogenase type 2 (HSD11B2; 11b HSD2); cyclooxygenase-2 (^TGS2; COX-2) A study in human samples and mice suggests that...
BC Innovations | Jul 24, 2008
Distillery Therapeutics

This Week in Therapeutics

This week in therapeutics Indication Target/marker/ pathway Summary Licensing status Publication and contact information Endocrine disease Diabetes; syndrome X 11 b-hydroxysteroid dehydrogenase type 1 (HSD11B1; 11b HSD1) An in vitro study identified piperazine sulfonamide derivatives...
Items per page:
1 - 4 of 4